Evidence map›Paper›PMID 28082519›Full record

Trial reportJournal of the American Society of Nephrology : JASN2017

Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia.

Steven Fishbane, Geoffrey A Block, Lisa Loram, John Neylan, Pablo E Pergola, Katrin Uhlig, Glenn M Chertow

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of the American Society of Nephrology : JASN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 2 pooled it
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 118 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2019
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Observational
  11. Review
  12. Article
  13. Oral and Intravenous Iron Therapy.Advances in experimental medicine and biology · 2025
    Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Steven FishbaneDivision of Nephrology, Department of Medicine, Hofstra Northwell School of Medicine, Mineola, New York.
Geoffrey A BlockDenver Nephrology, Denver, Colorado.
Lisa LoramKeryx Biopharmaceuticals Inc., Boston, Massachusetts.
John NeylanKeryx Biopharmaceuticals Inc., Boston, Massachusetts.
Pablo E PergolaRenal Associates Professional Association, San Antonio, Texas; and.
Katrin UhligKeryx Biopharmaceuticals Inc., Boston, Massachusetts.
Glenn M ChertowDivision of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, California gchertow@stanford.edu.
Colorado Kidney Care · USHofstra University · USRenal Associates P. A. · USStanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Iron deficiency anemia is common and consequential in nondialysis-dependent CKD (NDD-CKD). Efficacy and tolerability of conventional oral iron supplements are mixed; intravenous iron administration associates with finite but important risks. We conducted a randomized double-blind clinical trial in adults with NDD-CKD and iron deficiency anemia to compare the safety and efficacy of oral ferric citrate (

Indexed as

AdultAgedAged, 80 and overAnemia, Iron-DeficiencyDouble-Blind MethodFemaleFerric CompoundsHumansMaleMiddle AgedRenal Insufficiency, Chronicferric citrateFerric Compoundsanemiablood transfusionclinical trialhemoglobiniron deficiencyrenal dialysis

Identifiers

PMID28082519
PMCPMC5461803
OpenAlexW2572770153

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.